Evaluation of Therapeutic Effect of Intratrigonal Injection of AbobotulinumtoxinA(Dysport) and Hydrodistention in Refractory Interstitial Cystitis /Bladder Pain Syndrome
Vol. 18 No. 02 (2021),
3 May 2021
Purpose: There are two brands of BotulinumtoxinA(BTXA) that commonly used in treatment of Lower Urinary Tract Disease: OnabotolinumtoxinA(Ona-BTXA) and AbobotulinumtoxinA (Abo-BTXA). The present study was conducted to assess the potential therapeutic and adverse effect of Abo-BTXA or Dysport for IC/BPS.
Materials and Methods: Twenty-two out of 52 women diagnosed with IC/BPS who were refractory or had a low response to oral treatments of IC/BPS after 6 months, were included in the study. The end-point was O'Leary-Sant Score (OSS) including “symptoms” and “problem” indexes (ICSI and ICPI respectively) assessment after 1,3and 6 months after Abo-BTXA injection. Each patient underwent cystoscopy and immediately after hydrodistention received intratrigonal injections of 300 IU of Abo-BTXA (Dysport®) in30sites. The effect and side effects of this treatment over time have been investigated. Complications including high post void residual urine (PVR), bladder rupture, and urinary tract infections (UTI) were also assessed.
Results: The mean age of patients was 46.2±13.7 years and median OSS was 27.8±5.8.: After single injection ICSI, ICPI and total OSS significantly reduced in 1, 3, and 6 months follow up; rate of decrease total OSS was 39.5%, 36%, 18%, respectively. Its effect lasted up to six months and started to decrease after 1 months (p-value<0.05). Complications included urinary retention (PVR>200ml), bladder rupture, and UTI in 13.5%, 4.3%, and 18% of the patients, respectively.
Conclusion: intravesical injection of 300IU Abo-BTX(Dysport) could be a useful approach for the treatment of patients with refractory IC/BPS in a period of six months.
- Refractory Interstitial cystitis /Bladder Pain Syndrome
- Intravesicle Injection
How to Cite
Berry SH, Elliott MN, Suttorp M, Bogart LM, Stoto MA, Eggers P, et al. Prevalence of symptoms of bladder pain syndrome/interstitial cystitis among adult females in the United States. The Journal of urology. 2011;186(2):540-4.
Inoue Y, Mita K, Kakehashi M, Kato M, Usui T. Prevalence of painful bladder syndrome (PBS) symptoms in adult women in the general population in Japan. Neurourology and urodynamics. 2009;28(3):214-8.
Leppilahti M, Tammela TL, Huhtala H, Auvinen A. Prevalence of symptoms related to interstitial cystitis in women: a population based study in Finland. The Journal of urology. 2002;168(1):139-43.
Temml C, Wehrberger C, Riedl C, Ponholzer A, Marszalek M, Madersbacher S. Prevalence and correlates for interstitial cystitis symptoms in women participating in a health screening project. European urology. 2007;51(3):803-9.
Emil A, Tanagho M, Jack W, McAninch M. Smith's general urology. NewYork: Long Medical Books McGraw Hill, Medical Pub Division; 2008.
Elbadawi A, Light K. Distinctive ultrastructural pathology of nonulcerative interstitial cystitis. Urologia internationalis. 1996;56(3):137-62.
Urology C-W. vol. 4 of. Section XVII. 2012.
Smith CP, Radziszewski P, Borkowski A, Somogyi GT, Boone TB, Chancellor MB. Botulinum toxin A has antinociceptive effects in treating interstitial cystitis. Urology. 2004;64(5):871-5.
Gao Y, Liao L. Intravesical injection of botulinum toxin A for treatment of interstitial cystitis/bladder pain syndrome: 10 years of experience at a single center in China. International urogynecology journal. 2015:1-6.
Shiu-Dong Chung M, Yuh-Chen Kuo M, Hann-Chorng Kuo M. Intravesical onabotulinumtoxinA injections for refractory painful bladder syndrome. Pain Physician. 2012;15:197-202.
Akiyama Y, Nomiya A, Niimi A, Yamada Y, Fujimura T, Nakagawa T, et al. Botulinum toxin type A injection for refractory interstitial cystitis: A randomized comparative study and predictors of treatment response. International Journal of Urology. 2015;22(9):835-41.
Lee C-L, Kuo H-C. Intravesical botulinum toxin a injections do not benefit patients with ulcer type interstitial cystitis. Pain physician. 2013;16(2):109-16.
Simon LJ, Landis JR, Erickson DR, Nyberg LM, Group IS. The Interstitial Cystitis Data Base Study: concepts and preliminary baseline descriptive statistics. Urology. 1997;49(5):64-75.
Hanno PM, Burks DA, Clemens JQ, Dmochowski RR, Erickson D, FitzGerald MP, et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. The Journal of urology. 2011;185(6):2162-70.
O'Leary MP, Sant GR, Fowler FJ, Whitmore KE, Spolarich-Kroll J. The interstitial cystitis symptom index and problem index. Urology. 1997;49(5):58-63.
Grosse J, Kramer G, Stöhrer M. Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence. European urology. 2005;47(5):653-9.
Ruffion A, Capelle O, Paparel P, Leriche B, Leriche A, Grise P. What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU international. 2006;97(5):1030-4.
Rahnama'i MS, Marcelissen T, Apostolidis A, Veit-Rubin N, Schurch B, Cardozo L, et al. The efficacy of botulinum toxin A and sacral neuromodulation in the management of interstitial cystitis (IC)/bladder pain syndrome (BPS), what do we know? ICI-RS 2017 think thank, Bristol. Neurourology and urodynamics. 2018;37(S4):S99-S107.
Rosales R, Bigalke H, Dressler D. Pharmacology of botulinum toxin: differences between type A preparations. European Journal of Neurology. 2006;13(s1):2-10.
Jhang JF, Jiang YH, Kuo HC. Potential therapeutic effect of intravesical botulinum toxin type A on bladder pain syndrome/interstitial cystitis. International Journal of Urology. 2014;21(S1):49-55.
Apostolidis A, Popat R, Yiangou Y, Cockayne D, Ford A, Davis J, et al. Decreased sensory receptors P2X 3 and TRPV1 in suburothelial nerve fibers following intradetrusor injections of botulinum toxin for human detrusor overactivity. The Journal of urology. 2005;174(3):977-83.
Apostolidis A, Dasgupta P, Fowler CJ. Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. European urology. 2006;49(4):644-50.
Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin‐A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment–A prospective, multicenter, randomized, double‐blind, placebo‐controlled clinical trial. Neurourology and urodynamics. 2015.
Smith CP, Nishiguchi J, O’Leary M, Yoshimura N, Chancellor MB. Single-institution experience in 110 patients with botulinum toxin A injection into bladder or urethra. Urology. 2005;65(1):37-41.
Giannantoni A, Costantini E, Di Stasi SM, Tascini MC, Bini V, Porena M. Botulinum A toxin intravesical injections in the treatment of painful bladder syndrome: a pilot study. European urology. 2006;49(4):704-9.
Pinto R, Lopes T, Frias B, Silva A, Silva JA, Silva CM, et al. Trigonal injection of botulinum toxin A in patients with refractory bladder pain syndrome/interstitial cystitis. European urology. 2010;58(3):360-5.
Liu H-T, Kuo H-C. Intravesical botulinum toxin A injections plus hydrodistension can reduce nerve growth factor production and control bladder pain in interstitial cystitis. Urology. 2007;70(3):463-8.
Kuo HC, Chancellor MB. Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome. BJU international. 2009;104(5):657-61.
Pinto R, Lopes T, Costa D, Barros S, Silva J, Silva C, et al. Ulcerative and nonulcerative forms of bladder pain syndrome/interstitial cystitis do not differ in symptom intensity or response to onabotulinum toxin A. Urology. 2014;83(5):1030-4.
Pinto R, Lopes T, Silva J, Silva C, Dinis P, Cruz F. Persistent therapeutic effect of repeated injections of onabotulinum toxin a in refractory bladder pain syndrome/interstitial cystitis. The Journal of urology. 2013;189(2):548-53.
Kuo H-C. Repeated onabotulinumtoxin-a injections provide better results than single injection in treatment of painful bladder syndrome. Pain physician. 2013;16(1):15-23.
Kuo H-C. Preliminary results of suburothelial injection of botulinum a toxin in the treatment of chronic interstitial cystitis. Urologia internationalis. 2005;75(2):170-4.
Manning J, Dwyer P, Rosamilia A, Colyvas K, Murray C, Fitzgerald E. A multicentre, prospective, randomised, double-blind study to measure the treatment effectiveness of abobotulinum A (AboBTXA) among women with refractory interstitial cystitis/bladder pain syndrome. International urogynecology journal. 2014;25(5):593-9.
Ham BK, Kim JH, Oh MM, Lee JG, Bae JH. Effects of combination treatment of intravesical resiniferatoxin instillation and hydrodistention in patients with refractory painful bladder syndrome/interstitial cystitis: a pilot study. International neurourology journal. 2012;16(1):41.
Kuo HC. Repeated intravesical onabotulinumtoxinA injections are effective in treatment of refractory interstitial cystitis/bladder pain syndrome. International journal of clinical practice. 2013;67(5):427-34.
- Abstract Viewed: 0 times
- 5879/pdf Downloaded: 0 times